Investigating the anti-tumoral effect of curcumin on the mice in which Ehrlich ascites and solid tumor is created | ||
| Iranian Journal of Basic Medical Sciences | ||
| مقاله 12، دوره 22، شماره 4، تیر 2019، صفحه 418-425 اصل مقاله (668.38 K) | ||
| نوع مقاله: Original Article | ||
| شناسه دیجیتال (DOI): 10.22038/ijbms.2019.33623.8019 | ||
| نویسندگان | ||
| Seher Yilmaz* 1؛ Harun Ülger2؛ Tolga Ertekin3؛ Arzu Yay4؛ Mehtap Nisari2؛ Şerife Alpa5؛ Niyazi Acer2 | ||
| 1Department of Anatomy, Yozgat Bozok University Faculty of Medicine, Yozgat, Turkey | ||
| 2Department of Anatomy, Erciyes University Faculty of Medicine, Kayseri, Turkey | ||
| 3Department of Anatomy, Kocatepe University Faculty of Medicine, Afyon, Turkey | ||
| 4Department of Histology, Embriology, Erciyes University Faculty of Medicine, Kayseri, Turkey | ||
| 5Department of Anatomy, Karatay University Faculty of Medicine, Konya,Turkey | ||
| چکیده | ||
| Objective(s): In this study, the effects of different doses of curcumin application on Ehrlich ascites tumor (EAT) created in the mice of BALB/c type were investigated. Materials and Methods: Curcumin extracts can have hindering effect on tumor volume, vascular density, EAT cells around the tissues, and can support apoptosis. EAT cells (1x106) received from stock animals were injected intraperitoneally (IP) and subcutaneously (SC) to the animals. Then, curcumin was administered IP. Doses of 25 mg/kg IP and 50 mg/kg were administered over 10 days to the animals in the treatment groups in which ascites tumor was induced. The same doses were administered over 15 days in the treatment groups in which solid tumor was induced. Results: Histopathological examination in ascites tumor groups revealed that number of EAT cells at surrounding tissues was smaller in the group received 50 mg/kg curcumin when compared to tumor control group (P<0.05). The lowest increase in tumor volume was observed in the group received 25 mg/kg curcumin when compared to tumor control group (P<0.05). Conclusion: It was demonstrated once again in our study that curcumin had an anti-tumoral effect on both the development of ascites tumor created through EAT cells and the development of solid tumor. | ||
| کلیدواژهها | ||
| Animal؛ Apoptosis؛ Cell؛ Curcumin؛ Factor VIII؛ Injection؛ Mice | ||
| مراجع | ||
|
1. Nisari M, Yilmaz S, Eroz R, Ertekin T, Bircan D, Ulger H. The detection of curcumins’ antitumoral effects via argyrophilicnucleolar organizing region-associated protein synthesis in mice with ehrlich’s ascitic carcinoma. Bratisl Med J 2017; 118:61-65. 2. Merlo LM, Pepper JW, Reid BJ. Cancer as an evolutionary and ecological process. Nat Rev Cancer 2006; 6:924-935. 3. Gültekin M, Boztaş G: Breast cancer. T.C. Ministry of Health, Turkey Public Health Agency, Department of Cancer. http://www.who.int/mediacentre/factsheets/fs297/en/)date of access.22.11.2015; 20:00. 4. Odot J, Albert P, Carlıer A , Tarpın M, Devy J, Madoulet C. In vitro and in vivo antı-tumoral effect of curcumın agaınst melanoma cells. Int J Cancer 2004; 111:381-387. 5. Ertekin T , Bozkurt O , Eroz R , Nisari M , Bircan D , Nisari M , et al. May argyrophilic nucleolar organizing region-associated protein synthesis be used for selecting the most reliable dose of drugs such as rhamnetin in cancer treatments?. Bratisl Med J 2016; 117:653-658. 6. Akpolat M, Tarladaçalışır YT, Uz YH, Metin MS, Kızılay G. The place of curcumin in the treatment of cancer. New Med J 2010; 27:142-147. 7. Kocaaddam B, Şanlıer N. Curcumin, an active component of turmeric (Curcuma longa), and its effects on health. Crit Rev Food Sci Nutr 2015; 3:123-127. 8. Hatcher H, Planalp R, Cho J, Torti FM. Curcumin from ancient medicine to current clinical trials. Cell Moll Life 2008; 65:1631-1652. 9. Ozaslan M, Karagoz I, Kilic I, Güldür M. Ehrlich ascites carcinoma. Afr J Biotechnol 2011; 10:2375-2378. 10. Kaleoğlu Ö, İşli N. Ehrlich ascites tumour. Med J 1977; 40:978-984. 11. O’Reilly MS, Boehm T, Shing Y, Fukai N, Vasios G, Lane WS, et al. Endostatin: An endogenous inhibitor of angiogenesis and tumor growth. Cell 1997; 88:277-285. 12. Tozkoparan B, Aytaç SP. As a therapeutic target in cancer chemotherapy, glutathione S-transferases. Hacettepe Üniversity, J Fac Pharm 2007; 27:139-164. 13. Kızılcı S. Factors affecting the quality of life of cancer patients and their relatives receiving chemotherapy. J Nurs 1999; 3:18-26. 14. Özkan S. Psycho-Oncology. Istanbul Form Advertisement Services 2007; 104-106. 15. Zeybek Ü. Cancer research and experimental models. J Exp Med Res Ins 2013; 3:187-198. 16. Sharma RA, Gescher AJ, Steward WP. Curcumin: the story so far. Eur J Cancer 2005; 41:1955-1968. 17. Huang MT, Newmark HL, Frenkel K. Inhibitory effect of curcumin on tumorigenesis in mice. J Biochem Suppl 1997; 27:26-34. 18. Yu GW, Xu G, Ren JG, Xu X, Yuan HQ, Qi XL, et al. Preventive Action of Curcumin in Experimental Acute pancreatitis in mouse. İndian J Med Res 2011; 134:717-724. 19. Ueki M, Ueno M, Morishita J, Maekava N. Curcumin ameliorates cisplatin-induced nephrotoxicity by inhibiting renal inflammation in mice. J Biosci Bioeng 2013; 115:547-551. 20. Bhaumik S. Anjum R, Rangaraj N, Pardhasaradhi BV, Khar A. Curcumin mediated apoptosis in AK-5 tumor cells involves the production of reactive oxygen intermediates. Febs Lett 1999; 456:311-314. 21. Limtrakul P, Lipigorngoson S, Namwong O, Apisariyakul A, Dunn FW. Inhibitory effect of dietary curcuminon skin carcinogenesis in mice. Cancer Lett 1997; 116:197-203. 22. Armutak EI, Gültekin M. Effect of on apoptosis in vivo solid ehrlich ascites tumor model in Balb-C mice. J İstanbul Univ Vet Fac 2014; 40:183-190. 23. Choudhuri T, Pal S, Agwarwal ML, Das T, Sa G. Curcumin induces apoptosis in human breast cancer cells through p53-dependent bax induction. Febs Lett 2002; 512:334-340. 24. Somasundaram S, Edmund NA, Moore DT, Small GW, Shi YY, Orlowski RZ. Dietary curcumin ınhibits chemotherapy-induced apoptosis in models of human breast cancer. Cancer Res 2002; 62:3868-3870. 25. Weir NM, Selvendiran K, Kutula VK, Tong L, Vishwanath S, Rajaram M, et all. Curcumin induces G2/M arrest and apoptosis in cisplatin-resistant human ovariana cancer cells by modulating akt and p53 mAPK. Cancer Biol Ther 2007;6;178-184. 26. Hlatky L, Hahnfeldt P, Folkman J. Clinical application of antiangiogenic therapy: microvessel density, what it does and doesn’t tell us. J Natl Cancer Inst 2002; 94:883-893. 27. Yılmaz H, Ertekin T, Atay E, Nisari M, Güler SHAl Ö, Payas S, et al. Antioxidant role of melatonin against nicotine’s teratogenic effects on embryonic bone development. Iran J Basic Med Sci 2018; 21:787-793. 28. Delisser HM. Involvement of endothelial PECAM-1/CD31 in angiogenesis. Am J Pathol 1997; 151:671-677. 29. Azab ME, Hishe H, Moustapha Y, Awady ES. Anti-angiogenic effect of resveratrol or curcumin in Ehrlich ascites carcinoma-bearing mice. Eur J Pharmacol 2011; 652:7-14. 30. Abuelba H, Cotrutz CE, Stoıca BA, Stoica L, Olınıcı D, Petreuş T. In vitro evaluatio of curcmin effect on breast adenocarcinoma 2D and 3D cell cultures. Rom J Morphol Embryol 2015; 56:71-76. | ||
|
آمار تعداد مشاهده مقاله: 1,083 تعداد دریافت فایل اصل مقاله: 691 |
||